FDA requirement for Safety data for ANDAs SDTM [Regulatives / Guidelines]

posted by Sriraj – India, 2016-11-25 11:14 (2702 d 15:01 ago) – Posting: # 16812
Views: 4,765

Dear Member,

May I know whether for generic drugs BA/BE studies submission do we to report the safety data in SDTM/ADaM standards. Generally only the PK data would be reported and safety observations are discussed in the report. Do we need to collect safety in CDISC standards and submit SDTM datasets, do we need to have Table, listings, Graphs to be provided to FDA for generic drug BA/Be submissions. Or is it ok to provide PK data like pc/adpc pp/adpp and provide a safety report based on CRF pages collected data.

Thank you,
SriKanTH (SriRaj).

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,656 registered users;
93 visitors (0 registered, 93 guests [including 5 identified bots]).
Forum time: 03:15 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5